Linked Life Data

7093925

Source:http://linkedlifedata.com/resource/pubmed/id/7093925

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1982-9-24
pubmed:abstractText
Using case-control methods, we separately evaluated the risk of noncutaneous and cutaneous malignancy associated with exposure to methotrexate as it is used in the treatment of severe psoriasis. An analysis of 26 cases of noncutaneous cancer and 104 matched controls revealed no association between the development of noncutaneous malignancy and exposure to methotrexate (relative risk = 0.96; upper bound 95% confidence interval = 2.0). An analysis of 80 cases of nonmelanoma skin cancer and 297 matched controls revealed a relative risk of 1.2 for the development of cutaneous malignancy among those with exposure to methotrexate (upper bound 95% confidence interval = 1.9). Our data suggest that methotrexate, as it is used in the treatment of severe psoriasis, does not increase the risk of noncutaneous or cutaneous malignancy.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0008-543X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
50
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
869-72
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1982
pubmed:articleTitle
Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.